Quantcast

Latest Prostate-specific antigen Stories

2012-05-07 11:08:59

More efficient and accurate technique reported in the American Journal of Pathology While active monitoring of serum prostate specific antigen (PSA) levels in men over 50 has greatly improved early detection of prostate cancer, prediction of clinical outcomes after diagnosis remains a major challenge. Researchers from the University of Pittsburgh School of Medicine have found that a genetic abnormality known as copy number variation (CNV) in prostate cancer tumors, as well as in the benign...

2012-05-07 05:08:01

(Ivanhoe Newswire) -- Monitoring PSA levels in men over 50 has greatly improved early detection of prostate cancer, but prediction of clinical outcomes after diagnosis remains a major challenge. Now, researchers may have found a solution in your genes! Researchers from the University of Pittsburgh School of Medicine have found that a genetic abnormality known as copy number variation (CNV) in prostate cancer tumors, as well as in the benign prostate tissues adjacent to the tumor and in the...

2012-04-30 05:26:42

Despite recommendations in 2008 from the United States Preventive Services Task Force against testing for prostate cancer in men aged 75 years or older, almost half of men in that age group continue to get screening tests. In 2005, before the recommendations were released, 43 percent of men age 75 and above elected to take the prostate-specific antigen (PSA) test. In August 2008, the Task Force stated it "recommends against the service," arguing "there is moderate or high certainty the...

2012-04-09 21:46:42

Discovery of inherited-genetic variations may help assess a patient's risk of life-threatening disease before it strikes An international research team led by Weill Cornell Medical College investigators have discovered two inherited-genetic deletions in the human genome linked to development of aggressive prostate cancer. The findings, published online today in the Proceedings of the National Academy of Sciences (PNAS), indicate a man's risk of developing prostate cancer either triples or...

2012-04-09 05:40:35

(Ivanhoe Newswire) -- Do you or someone you know suffer from advanced prostate cancer (CRPC)? A new treatment may be available that can help treat the deadly disease. Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that occurs when the disease progresses after treatment with androgen deprivation therapy. A drug called galeterone works against CRPC by blocking the androgen receptor, reducing levels of the ligand that binds to the receptor and degrading...

2012-04-02 09:22:59

Phase 1 data presented at AACR Annual Meeting 2012; Study showed no dose limiting toxicities with galeterone; Preliminary efficacy data reported Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study. The data will be...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related